Batu Biologics, Inc.

San Diego, CA 92121, US

Batu Biologics is an immuno-oncology company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer”: the tumor blood vessels.

Angiogenesis, or the process of new blood vessel formation, is essential for the growth and metastasis of solid tumors. Tumors cannot grow larger than 1-2 millimeter in diameter without stimulating new blood vessels to feed them. Blocking this process has led to the development of multibillion-dollar blockbuster drugs such as Avastin ($7 billion 2015), Sunitinib ($1.1 billion 2016), and Revlimed ($3.2 billion 2011). Unfortunately these drugs target only one pathway of the angiogenesis process, and as a result tumor remissions are temporary, and in many cases not sustainable.

Batu Biologics’ flagship therapeutic, ValloVax™, is based on harnessing the immune system’s ability to selectively seek and destroy tumor-associated blood vessels, while sparing non-malignant blood vessels. In contrast to previous anti-angiogenic approaches, ValloVax™ stimulates the immune system to attack multiple pathways necessary for angiogenesis, thus having the potential for superior efficacy in the treatment of solid tumors. Batu Biologics sees the ValloVax™ platform as a powerful new immunotherapeutic approach to treating cancer that works synergistically with several already FDA approved drugs, and plans to develop the program clinically for multiple solid tumor indications.

Batu Biologics has recently received FDA regulatory clearance of our Investigational New Drug Application, enabling the Company to proceed with a Phase I study for patients with metastatic non small cell lung cancer.

General Information


Social Links

Company Industry

Select Industry:

Company Description

0 / 250
0 / 2000


Prior Year Revenue Current Year Revenue Next Year Revenue
Company Age Employees Sub-Industry
6 years, 8 months 7 Biotechnology – Drugs

Company Financials

Viewable by EquityNet investors only

Company Age & Size



0 / 1000
Chief Executive Officer
Samuel Wagner

Samuel WagnerSamuel Wagner is a founder of Batu Biologics and has served as its President and Chief Executive Officer since January of 2014. Mr. Wagner studied engineering at an honors level at the University of California at San Diego, but pursued an entrepreneurial path. Following a successful series of investments in various ventures, Mr. Wagner took a strong interest in biotechnology, where he is self-taught. He has since connected with leading biotechnology minds in San Diego and spear-headed their collaboration while garnering significant private investment. Mr. Wagner hopes to improve the lives of patients with devastating diseases by organizing and leading teams of highly qualified individuals to develop innovative therapeutics. He further seeks to utilize the success of Batu Biologics and future endeavors to drive his thirst for scientific entrepreneurship, and to give back to the communities that inspire him.

Chief Operating Officer
Dimitri Theofilopoulos, J.D.

 Dimitri Theofilopoulos, J.D.Dimitri Theofilopoulous oversees operations and legal matters for Batu Biologics. Dimitri was in-house business counsel for consulting transactions and research compliance at The Scripps Research Institute from June 2010 – March 2013. Prior to that, he practiced employment and healthcare law. Dimitri holds a J.D. from USC School of Law and a B.A. in History from UCLA. He has also published The Bar Exam Memorization Book, a useful study aid for the bar exam.

Vice President Business Development
Hong Ma, MD, Ph.D., M.B.A.

Hong Ma, MD, Ph.D., M.B.A.Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.

Chief Financial Officer
Gerry Berg

Gerry BergMr. Berg has over 30 years of senior management experience working with private and public companies. Mr. Berg has served a number of public companies as their Chief Executive Officer, President, Chief Financial Officer or as a financial consultant. He has also served on the Board of Directors for a number of public companies. Mr. Berg began his career as a Certified Public Accountant with the firm of Deloitte & Touche (Deloitte). He served as Audit Manager for the Buick Motor Division of General Motors Corporation as one of his primary assignments. Mr. Berg holds a Bachelors of Arts in Accounting from Walsh College where he graduated Cum Laude. Mr. Berg became a Certified Public Accountant (CPA) in the State of Michigan in 1979 and in the State of California in 1984.

Vijay Mahant, Ph.D.

Vijay Mahant, Ph.D.Dr. Mahant graduated from LUT (UK) and he received his second post-doctorate from UT Health Science Center at Houston/MD Anderson, TX, USA). Dr. Mahant is a scientist and an entrepreneur with 30 years of experience in immuno- and molecular diagnostics. He has held executive positions and he is founder/co-founder of diagnostic companies with diverse experiences in RD, worked with hospitals /medical institutes such as Mayo Clinic (‘87-’89, “New Generation” ultra-sensitive TSH test (evaluated and validated by Dr. George Klee , President of American Thyroid Association ) and worked (2005) with Long Beach Memorial Hospital in setting up a molecular diagnostic lab. Dr. Mahant has been involved in fund raisings, Initial Public Offerings (IPOs) and he has 25 issued patents and 15 patents pending; he has authored and/or co-authored publications. He has developed more than 35 products with multi million dollars in revenues.

Chief Physician/Medical Officer
Santosh Kesari, M.D., Ph.D., FANA

Santosh Kesari, M.D., Ph.D., FANADr. Kesari is one of “America’s Top Doctors” selected by Castle Connolly Medical Ltd. He is among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd. Each year, Castle Connolly surveys thousands of physicians and other healthcare professionals and asks them to identify excellent doctors in every specialty in their region and throughout the nation for their Top Doctors™ distinction. Dr. Kesari is often called upon by the media to comment on neurological issues and the non-surgical treatment of brain tumors. Dr. Kesari is currently the Chair and Professor of the Department of Translational Neurosciences and Neurotherapeutics at the John Wayne Cancer Institute.

Investors / Lenders

Add investors/lenders that are already on EquityNet by typing their name and then selecting them from the drop-down.
Add investors/lenders that are not yet on EquityNet by typing their name, selecting "Add a New Investor", and filling in additional information.

Invested Amount:
Individual Investor
Alan J Lewis, Ph.D.

Dr. Lewis is an industry veteran with over 37 years of experience as an executive in the life science industry. He spent 15 years at the pharmaceutical company Wyeth-Ayerst, where he was Vice President of Research, leading translational research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. He later became the CEO of Signal Pharmaceuticals, a company focusing on small-molecule drug discovery and development, which was eventually acquired by Celgene in 2010. Subsequent to his employment as President of Celgene, Dr. Lewis had several successful business ventures, including raising $27 million as CEO of Novocell, becoming the CEO of the Juvenile Diabetes Research Foundation, and raising over $45 million as CEO of Ambit.

Individual Investor
Vladimir Bogin, MD, FACP

Dr. Bogin started his medical training at Moscow Medical Academy, then trained at Yale and Brown Universities and received his postgraduate training at the University of Rochester where he was also elected to a chief medical resident position. Vlad has been involved in the drug development cycle for over 15 years, from basic discovery research to clinical trial design and multinational phase III and IV trials. As the director at Boehringer Ingelheim he was in charge of late stage development of a leading cardiology product. As the Chairman of the Board at Medistem Inc. Vlad was instrumental in its advancement from preclinical to clinical stage, from a non-reporting to a fully reporting publicly trading company and for subsequent successful liquidity event in 2014. Vlad is founder and CEO of Cromos Pharma, a clinical research organization that has conducted over a hundred clinical trials in Eastern Europe and in former Soviet republics.

Individual Investor
John Peck Jr.

John Peck Jr graduated from Northern Illinois University in 1966 with a BS in Business. He spent the next three years in the US Army as an ordinance officer stationed in Southeast Asia. Upon returning to the States in 1969 he worked for RCA and Intel while pursuing an MBA at Depaul University. In 1976 John joined Meridian Leasing as employee number 5. In 1994 John (now CEO) and a Partner purchased Meridian Leasing (now 150 strong) from ownership that was in a consolidation mode. John’s share was bought out in 1997 and he started investing in commercial real estate with an emphasis on the large Multifamily properties. Currently John is doing a little land development work and has found the “New Wave of the Future”in the Biotech Community. At present he is invested in 7 Biotech firms. John and his wife,Vera, have been married for over 45 years and have had two children.



Funding Goal$3,000,000

Funding Raised So Far$0

Funding Commitments$500,000

Funding Remaining$2,500,000

Funding TypeEquity

Pre-Money Valuation

Investor Ownership

Interest / Dividend

Previous Funding

General Funding


Showing your General Funding information publicly may constitute general solicitation. General solicitation is a new commonly-used way for companies to raise funding. To learn about general solicitation, consult your legal counsel. If you uncheck this box, your General Funding information will be viewable to only EquityNet investors.

Private Funding

Viewable by EquityNet investors only


Batu Biologics, Inc. Image 1



Complete a Business Plan in EquityNet

Your EquityNet business plan is only viewable to capital providers and business supporters that you choose to share with in the “Crowdfund” or “Messages” tab. Investors prefer an EquityNet business plan. Entering a plan is highly educational and improves your appeal to investors.

Upload Documents

Document file names will be viewable by EquityNet investors and business supporters only. Actual documents are only viewable to capital providers and business supporters that you choose to share with in the “Crowdfund” or “Messages” tab.

Share Your Public Profile Page

Users who follow all these tips increase their fundraising odds substantially.

  • Email your public page to all your LinkedIn contacts.
    • Post your page to your LinkedIn profile page.
  • Email your public page to all your Facebook contacts.
    • Post your page to your Facebook profile page.
  • Email your public page to all your Twitter contacts.
    • Post your page to your Twitter profile page.
  • Put your public page up on your website.
    • Don't have a website yet? Use this page as your site!
  • Share your page link anywhere there's a listing for your company.
    • Press Releases, Crunchbase, Wikipedia, Blogs, etc...
  • Email your public page to all your email contacts.
    • Use Outlook, Gmail, Yahoo Mail, Hotmail, etc...

Your Public Profile Page:

Would you like to share your public profile page with your email contacts?